AcornMed, one of the brands under Xiangxin Biotechnology, specializes in solid tumor genetic testing and blood tumor genetic testing. The other brand, Xiangxin Technology, focuses on the development, production, and sales of in vitro diagnostic reagents. The company was founded in 2018 and is based in Beijing, China.
Expert Collections containing AcornMed
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AcornMed is included in 1 Expert Collection, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Latest AcornMed News
Apr 28, 2021
Save for later NEW YORK – Molecular diagnostics firm NuProbe said Tuesday that it has reached a strategic collaboration agreement with Beijing-based AcornMed Biotechnology to develop products for minimal residual disease detection in genitourinary tract cancer and hematological cancer using NuProbe's blocker displacement amplification, or BDA, technology. Based in Shanghai and Houston, NuProbe has developed a PCR enrichment technology to reduce wild-type amplification efficiency and enhance low-frequency mutation signals. According to the company, this allows its BDA method to selectively amplify low-abundance variants in a background of wild-type DNA. The technology is broadly compatible with various molecular diagnostic platforms including PCR, first-generation capillary sequencing, next-generation high-throughput sequencing, third-generation single-molecule sequencing, and mass spectrometry of nucleic acids. NuProbe and AcornMed aim to validate the chemistry for repeat testing of urine or plasma samples to monitor cancer treatment efficacy and guide clinician decision-making. Feng Lou, chief technology officer and cofounder of AcornMed, said in a statement that the BDA technology's ability to increase mutation detection sensitivity makes it "very suitable for MRD detection products." "AcornMed is the only company with both a proprietary genomic database in genitourinary tract tumors and the most comprehensive genomic database of blood malignancies in China," added Yingshuang Chai, CEO of NuProbe. "Combining their resources with our highly sensitive BDA technology, we expect to bring revolutionary products to the oncology field." Financial terms of the agreement were not disclosed.
AcornMed Frequently Asked Questions (FAQ)
When was AcornMed founded?
AcornMed was founded in 2018.
Where is AcornMed's headquarters?
AcornMed's headquarters is located at Room 5036, 5th Floor, 19 Haidian South Road, Beijing.
What is AcornMed's latest funding round?
AcornMed's latest funding round is Series B.
How much did AcornMed raise?
AcornMed raised a total of $42.93M.
Who are the investors of AcornMed?
Investors of AcornMed include Elikon Venture, Yikai Ventures, Qingdao Hongteng, Wushi Capital, Yushan Partners and 6 more.